Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | BCHE | P06276 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658479 | 0.86 | ACHE (0.76) | ACHEBCHE | |
| SCHEMBL3098485 | 0.85 | ACHE (0.78) | ACHEOPRM1SIGMAR1 | |
| SCHEMBL19652159 | 0.83 | ACHE (0.60) | ACHEBCHE | |
| SCHEMBL19658394 | 0.83 | ATM (0.53) | ACHEOPRM1SIGMAR1 | |
| SCHEMBL7269086 | 0.81 | OPRM1 (0.72) | ACHEOPRM1SIGMAR1 | |
| SCHEMBL28169833 | 0.80 | CCR3 (0.65) | ACHESIGMAR1BCHE | |
| SCHEMBL9477536 | 0.79 | ACHE (0.69) | ACHEBCHE | |
| SCHEMBL24607237 | 0.78 | SMN1; SMN2 (0.44) | ACHEOPRM1 | |
| SCHEMBL3086835 | 0.78 | ACHE (0.69) | ACHEOPRM1SIGMAR1 | |
| SCHEMBL14601860 | 0.78 | ACHE (1.00) | ACHEOPRM1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | ACHE 2649/4885OPRM1 4350/4885SIGMAR1 1530/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | ACHE 2649/4885OPRM1 4350/4885SIGMAR1 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.